Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
REGULATORY
Regional Formulary Push Pops Up from Ishin at 3-Party Talks
The opposition Japan Innovation Party (Nippon Ishin) made an abrupt proposal to promote regional drug formularies as part of measures to reduce healthcare spending at its three-way talks with the ruling bloc on May 15. In a meeting with the…
To read the full story
Related Article
- Ruling Bloc, Ishin Agree to Discuss Coverage of OTC-Like Drugs
June 12, 2025
- 3 Parties Agree to Review OTC-Like Drugs from FY2026, but Details Still in the Air
June 9, 2025
- Ishin Nixes Ruling Bloc’s Draft Social Security Plans over OTC-Like Drug Issue
May 30, 2025
- Topic of OTC-Like Drugs Dropped from 3-Party Talks: Ishin
May 27, 2025
- Impact of Nationwide Implementation of Regional Formularies “Difficult to Estimate”: MHLW Official
May 23, 2025
- OTC-Like Drug Is Hardest Topic in Tripartite Social Security Talks: Japan PM
May 22, 2025
- Ruling Bloc, Ishin Reach No Deal on Coverage of OTC-Like Drugs
May 8, 2025
- MHLW to Present Estimate on Coverage Removal of OTC-Like Meds at 3-Party Talks
April 24, 2025
- Ruling Coalition Wary of Scrapping Coverage for OTC-Like Drugs
April 21, 2025
- Medical Advocacy Group Condemns Plan to Remove Coverage for OTC-Like Drugs
April 17, 2025
- Scrap Coverage for OTC-Like Drugs with Same APIs and Dose as OTC Meds: Nippon Ishin
April 14, 2025
- 3-Party Talks Fail to Reach Specifics on OTC-Like Drugs
April 4, 2025
- Three-Party Talks to Be Held on Health Coverage of OTC-Like Drugs: Minister
March 4, 2025
REGULATORY
- Japan Govt Council Discusses Draft Recommendations for National MCM Strategy
December 9, 2025
- MHLW Eyes Govt-Led Ingredient Lists for Regional Formularies: LDP Briefing
December 9, 2025
- JMA Pushes Back on Incentives Tied to Regional Formularies: Chuikyo
December 9, 2025
- PMDA to Adopt General-Purpose AI in FY2025, Eyes Specialized Tools for Reviews and Safety Work
December 8, 2025
- Japan Likely to Extend Generic-Name Prescribing Premium to Biologics to Spur Biosimilars
December 8, 2025
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…